Concord Biotech Ltd.

1474.95 +34.70 ▲2.4%

23 February 2024, 04:01:00 PM
Volume: 6,049

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.concordbiotech.com
Market Cap 15,426.71 Cr.
Enterprise Value(EV) 15,370.56 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 22.95 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 64.26 Trailing Twelve Months Ending 2023-03
Industry PE 41.88 Trailing Twelve Months Ending 2023-03
Book Value / Share 136.58 Trailing Twelve Months Ending 2023-03
Price to Book Value 10.80 Calculated using Price: 1,474.60
Dividend Yield 0.46 Period Ending 2023-03
No. of Shares Subscribed 10.46 Cr. 104,616,204 Shares
FaceValue 1
About Concord Biotech Ltd.
The company is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.

Concord Biotech Ltd. Delivery

Delivered Qty
Traded Qty

Concord Biotech Ltd. Performance

1 Day
+2.41%
1 Week
+4.90%
1 Month
+5.80%
3 Month
+16.80%
6 Month
+48.47%
1 Year
2 Year
5 Year
10 Year

Concord Biotech Ltd. Fundamental Ratios

4 years 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 21.94 26.55 16.64 20.06
Return on Capital Employed (%) 26.23 32.96 21.66 26.7
Return on Assets (%) 16.11 19.89 12.43 15

Concord Biotech Ltd. Balance Sheet

Particulars 5 years 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 770 999 1,103 1,290 1,354
Non Curr. Liab. 55 77 54 32 29
Curr. Liab. 223 236 344 376 167
Minority Int.
Equity & Liab. 1,049 1,313 1,502 1,699 1,551
Non Curr. Assets 510 706 869 971 795
Curr. Assets 539 607 633 728 756
Misc. Exp. not W/O
Total Assets 1,049 1,313 1,502 1,699 1,551

Concord Biotech Ltd. Profit and Loss

Particulars 4 years 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Net Sales 512 617 713 853
Other Income 31 14 23 35
Total Income 544 631 736 888
Total Expenditure -308 -289 -439 -505
PBIDT 236 342 297 384
Interest -1 -1 -6 -10
Depreciation -21 -28 -50 -54
Taxation -45 -78 -63 -82
Exceptional Items
PAT 169 235 175 240
Minority Interest
Share Associate
Other Related Items 0
Consolidated Net Profit 169 235 175 240
Adjusted EPS 16 22 17 23

Concord Biotech Ltd. Cash Flow

Particulars 4 years 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 155 167 207 246
Cash Fr. Inv. -113 -195 -112 -158
Cash Fr. Finan. -43 31 -100 -85
Net Change -1 3 -4 3
Cash & Cash Eqvt 2 5 1 4

Concord Biotech Ltd. Shareholding Pattern

2 Qtrs 2023-09 (%) 2023-12 (%)
Promoter 44.08 44.08
Public 55.92 55.92
Depository Receipts 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00

Concord Biotech Ltd. Announcements

Thu, 22 Feb 2024
Intimation About Closure Of Inspection Of Ministry Of Health Pharmacy And Poisons Board Republic Of Kenya At Valthera (Unit II) Of The Company
In compliance with the Reg. 30 of LODR we hereby notify that Ministry of Health Pharmacy and Poisons Board Republic of Kenya had conducted inspection of Unit II (Formulation facility) of the Company located at Valthera- Dholka (Unit II) in Ahmedabad Gujarat. the said inspection has been completed successfully without any adverse remarks and the company has received the certificate of Good Manufacturing practices (GMP) as on today (i.e. 22/02/2024)
Fri, 16 Feb 2024
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In Continuation of our letter dated February 09 2024 regarding audio recording of the unaudited (Standalone and Consolidated) financial results of the company for the Third Quarter and Nine months ended December 31 2023 transcripts of the earnings call for the said period enclosed herewith and available on the website of the company at the following link after sending this letter to you https://www.concordbiotech.com/investors
Tue, 13 Feb 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the officials of the Company will be Meeting Investors (Participants) in the enclosed intimationDiscussions will be based on publicly available information.No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.This information is submitted to you pursuant to Regulation 30 (6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.Kindly note that changes may happen due to exigencies on the part of Host / Participants / Company.

Concord Biotech Ltd. Technical Scans

Fri, 23 Feb 2024
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High
Close Within 52 Week High Zone Close Within 52 Week High Zone
High Increase in 1 Month High Increase in 1 Month

Concord Biotech Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 374,572.18 1,560.95 +0.2%
Cipla Ltd. 118,375.92 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. 107,511.08 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. 97,345.81 6,742.15 -0.4%
Divi's Laboratories Ltd. 96,748.70 3,636.05 -0.3%
Zydus Lifesciences Ltd. 93,335.34 922.10 +1.9%
Torrent Pharmaceuticals Ltd. 88,913.00 2,627.10 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 42.06 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-12 31.92 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.56 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 123.33 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-12 69.96 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.39 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 59.51 2,627.10 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.00 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-12 4.57 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 4.00 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 14.41 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-12 7.42 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.80 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.43 2,627.10 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 0.02 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,627.10 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,627.10 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,627.10 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,627.10 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,627.10 +0.7%

Concord Biotech Ltd. FAQ's

What is Concord Biotech share price?

Can I buy Concord Biotech shares now?

What is the Dividend Yield of Concord Biotech?

What is the Market Cap of Concord Biotech?

What are the key metrics to analyse Concord Biotech?

What is the 52 Week High and Low of Concord Biotech?

What is the trend of Concord Biotech share price?